<% strRCName="Atrial Fibrillation and Anticoagulation" %> <% strRCPage="Atrial Fibrillation(emerg)" %>
eMedicine World Medical Library

Excerpt from Atrial Fibrillation


Synonyms, Key Words, and Related Terms: AF, atrial fib, bradyarrhythmia, tachyarrhythmia, arrhythmia, heart disease, acute myocardial infarction, AMI, congestive heart disease, CHD, coronary artery disease, CAD, cardiovascular disease, heart attack, rhythm disturbance, atrioventricular node, AV node, palpitations, dyspnea, chest pain, angina, syncope, hypotension, transient ischemic attacks, TIAs, stroke, peripheral arterial embolization, congestive heart failure, CHF, jugular venous distension, hypertension, valvular heart disease, rheumatic heart disease, left ventricular hypertrophy, diabetes mellitus, pulmonary embolism, cardiomyopathy, infiltrative heart disease, sick sinus syndrome, pericarditis, hyperthyroidism, ethanol use (holiday heart), substance abuse

Please click here to view the full topic text: Atrial Fibrillation

Background

Atrial fibrillation (AF), the most commonly encountered arrhythmia in clinical practice, is defined by the absence of coordinated atrial systole. AF results from multiple reentrant electrical wavelets that move randomly around the atria.

P waves are replaced by irregular, chaotic fibrillatory waves, often with a concomitant irregular ventricular tachycardia. The rate at which the atrial electrical impulses are transmitted to the ventricle is determined by a number of factors including relative refractory period within the atrioventricular (AV) node, hydration status, and presence or absence of pharmacologic agents used to control the rate. When ventricular rate increases to tachycardic levels, a situation of atrial fibrillation with rapid ventricular response (AF with RVR) ensues. This in turn can lead to decompensation in the form of either myocardial ischemia or creation of congestive heart failure (CHF).

AF may increase mortality up to 2-fold, primarily due to embolic stroke. This risk exists as the lack of coordinated atrial contraction leads to unusual fluid flow states through the atrium that are permissive for formation of thrombus that is then at risk to embolize. This risk is theoretically particularly present upon return to normal sinus rhythm when coordinated atrial contraction can entrain a thrombus into flow. The risk of embolism associated with cardioversion is stated to be as high as 2%. Thus, part of the challenge for emergency physicians is the question of managing rate versus rhythm in the ED and the issue of when cardioversion through any mechanism should be attempted.

The incidence of atrial fibrillation increases significantly with advancing age.

Managing AF in the ED, for the most part, involves a straightforward approach. Generally accepted guidelines and protocols for managing AF are of great value in the decision-making process (see Media files 1-6).

The cardiologist's approach to AF is well covered in Dr Rosenthal's article, Atrial Fibrillation. Emergency physicians are more concerned with the acute life threat and appropriate ED treatment of patients with AF; however, readers who are interested in topics such as catheter ablation and clinical electrophysiology of AF are referred to Dr Rosenthal's article. For additional resources, please also visit Medscape's Atrial Fibrillation Resource Center.

Pathophysiology

Multiple reentrant waveforms within the atria bombard the AV node, which becomes relatively refractive to conduction due to the frequency of upstream electrical activity.

Three mechanisms that have been shown to play a role in the initiation and maintenance of AF include the following:

  • Enhanced automaticity in the left atrium extending to proximal 5-6 mc portions of the pulmonary veins
  • Electrical remodeling of the atria with resultant shortening of the atrial refractory period increases the duration and stability of AF, well-described by the phrase "atrial fibrillation begets atrial fibrillation"
  • In chronic AF, areas of functional conduction block further divide and maintain a persistently chaotic electrical state.

Inflammation is believed to play an as-of-yet undefined role in the pathogenesis of AF.

AF occurs in 3 distinct clinical circumstances:

  • As a primary arrhythmia in the absence of identifiable structural heart disease
  • As a secondary arrhythmia in the absence of structural heart disease but in the presence of a systemic abnormality that predisposes the individual to the arrhythmia
  • As a secondary arrhythmia associated with cardiac disease that affects the atria

While differing classification schemes exist, AF is commonly broken down into acute versus chronic AF, with chronic AF then being subcategorized into one of the following:

  • Paroxysmal - Duration less than 7 days, with spontaneous termination
  • Persistent - Duration greater than 7 days and would last indefinitely unless cardioverted
  • Permanent - Duration greater than 7 days, with restoration to sinus rhythm not possible
  • Lone AF has been used to describe AF in individuals without structural or cardiac or pulmonary disease, with low risk for thromboembolism. It has traditionally been applied to patients younger than 60 years.

The 3 primary ways AF affects hemodynamic function include the following:

  • Loss of atrial kick (synchronized atrial mechanical activity)
  • Irregularity of ventricular response
  • Inappropriately rapid heart rate

Frequency

United States

Approximately 2.5 million Americans, or close to 1% of the total population, currently have atrial fibrillation.

Atrial fibrillation can be considered a disease of aging, and with the projected increase in the elderly population in America, the prevalence is expected to more than double by the year 2050.

Mortality/Morbidity

  • The rate of ischemic stroke among patients with nonrheumatic AF averages 5% a year, which is somewhere between 2-7 times the rate of stroke in patients without AF. The risk of stroke is not due solely to AF; it increases substantially in the presence of other cardiovascular disease.
  • The attributable risk of stroke from AF is estimated to be 1.5% for those aged 50-59 years, and it approaches 30% for those aged 80-89 years.
  • The total mortality rate is approximately doubled in patients with AF compared with patients in normal sinus rhythm and is linked with the severity of underlying heart disease.
  • AF complicates acute myocardial infarction (AMI) in 5-10% of cases. The causes of AF in AMI are thought to be due to any number of factors, such as atrial infarction, atrial ischemic injury, atrial distension, or, perhaps, pericarditis. According to Rathore et al, patients who developed new-onset AF during the course of myocardial infarction (MI) were at higher risk than patients who presented with chronic AF. Patients with AMI and AF tend to be older, be less healthy, and have poorer outcomes during hospitalization and after discharge than individuals without AF. AF is independently associated with an increased mortality rate.

Race

  • Atrial fibrillation appears to be more common in whites than in blacks.
  • Blacks have less than half the age-adjusted risk of developing AF than is seen in whites.

Sex

Incidence is significantly higher in men than in women in all age groups.

Age

The prevalence of atrial fibrillation increases almost exponentially with age.

AF is uncommon in childhood except after cardiac surgery.

  • The prevalence of AF among persons younger than 55 years is 0.1%.
  • The prevalence of AF among persons 60 years or older is 3.8%.
  • The prevalence of AF among persons 80 years or older is 10%.

Please click here to view the full topic text: Atrial Fibrillation

About Us | Privacy | Code of Ethics | Terms of Use | Contact Us | Advertising | Institutional Subscribers
Labelled with ICRA © 1996-2006 by WebMD.
All Rights Reserved.

Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER